Potency of CR 1409, a new proglumide analog, on cholecystokinin-mediated behaviors and receptor binding

Maria Th Kaltwasser, Barbara Petrack, Jacqueline Crawley

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Behavioral and receptor binding techniques were employed to evaluate the potency of CR 1409, a new analog of proglumide, as a cholecystokinin antagonist. CR 1409, at doses of 1 mg/kg i.p. in mice, effectively blocked the inhibition of feeding and exploratory behaviors induced by cholecystokinin. In rats, CR 1409 alone, at doses of 1 and 10 mg/kg, did not affect feeding or exploratory behaviors, but at 25 mg/kg alone, CR 1409 reduced food intake and exploratory behaviors, suggesting a mixed agonist-antagonist profile. On these several behavorial parameters, CR 1409 antagonized peripherally administered cholecystokinin with 10-1000 times greater potency than that reported for proglumide (Crawley et al., J. Pharmac. Exp. Ther. 236, 320-330, 1986). In binding to pancreatic cholecystokinin membranes, CR 1409 was more than 100,000-times more potent than that reported for proglumide (Rovati, Scand. J. Gastroenterol. 11, 113-118, 1976). CR 1409 inhabited binding of 125-I-cholecystokinin octapeptide in mouse parcreatic and brain membranes with IC50 values of 13.7 nM and 2.6 μM, respectively, demonstrating its selectivity for peripheral-type CCK receptors.

Original languageEnglish (US)
Pages (from-to)547-553
Number of pages7
JournalNeurochemistry International
Volume10
Issue number4
DOIs
StatePublished - 1987
Externally publishedYes

Fingerprint

Proglumide
Cholecystokinin
Exploratory Behavior
Feeding Behavior
Cholecystokinin Receptors
Sincalide
Membranes
lorglumide
Inhibitory Concentration 50
Eating

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Cellular and Molecular Neuroscience

Cite this

Potency of CR 1409, a new proglumide analog, on cholecystokinin-mediated behaviors and receptor binding. / Kaltwasser, Maria Th; Petrack, Barbara; Crawley, Jacqueline.

In: Neurochemistry International, Vol. 10, No. 4, 1987, p. 547-553.

Research output: Contribution to journalArticle

@article{30dee5340db243e6925f902897065f5f,
title = "Potency of CR 1409, a new proglumide analog, on cholecystokinin-mediated behaviors and receptor binding",
abstract = "Behavioral and receptor binding techniques were employed to evaluate the potency of CR 1409, a new analog of proglumide, as a cholecystokinin antagonist. CR 1409, at doses of 1 mg/kg i.p. in mice, effectively blocked the inhibition of feeding and exploratory behaviors induced by cholecystokinin. In rats, CR 1409 alone, at doses of 1 and 10 mg/kg, did not affect feeding or exploratory behaviors, but at 25 mg/kg alone, CR 1409 reduced food intake and exploratory behaviors, suggesting a mixed agonist-antagonist profile. On these several behavorial parameters, CR 1409 antagonized peripherally administered cholecystokinin with 10-1000 times greater potency than that reported for proglumide (Crawley et al., J. Pharmac. Exp. Ther. 236, 320-330, 1986). In binding to pancreatic cholecystokinin membranes, CR 1409 was more than 100,000-times more potent than that reported for proglumide (Rovati, Scand. J. Gastroenterol. 11, 113-118, 1976). CR 1409 inhabited binding of 125-I-cholecystokinin octapeptide in mouse parcreatic and brain membranes with IC50 values of 13.7 nM and 2.6 μM, respectively, demonstrating its selectivity for peripheral-type CCK receptors.",
author = "Kaltwasser, {Maria Th} and Barbara Petrack and Jacqueline Crawley",
year = "1987",
doi = "10.1016/0197-0186(87)90083-0",
language = "English (US)",
volume = "10",
pages = "547--553",
journal = "Neurochemistry International",
issn = "0197-0186",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Potency of CR 1409, a new proglumide analog, on cholecystokinin-mediated behaviors and receptor binding

AU - Kaltwasser, Maria Th

AU - Petrack, Barbara

AU - Crawley, Jacqueline

PY - 1987

Y1 - 1987

N2 - Behavioral and receptor binding techniques were employed to evaluate the potency of CR 1409, a new analog of proglumide, as a cholecystokinin antagonist. CR 1409, at doses of 1 mg/kg i.p. in mice, effectively blocked the inhibition of feeding and exploratory behaviors induced by cholecystokinin. In rats, CR 1409 alone, at doses of 1 and 10 mg/kg, did not affect feeding or exploratory behaviors, but at 25 mg/kg alone, CR 1409 reduced food intake and exploratory behaviors, suggesting a mixed agonist-antagonist profile. On these several behavorial parameters, CR 1409 antagonized peripherally administered cholecystokinin with 10-1000 times greater potency than that reported for proglumide (Crawley et al., J. Pharmac. Exp. Ther. 236, 320-330, 1986). In binding to pancreatic cholecystokinin membranes, CR 1409 was more than 100,000-times more potent than that reported for proglumide (Rovati, Scand. J. Gastroenterol. 11, 113-118, 1976). CR 1409 inhabited binding of 125-I-cholecystokinin octapeptide in mouse parcreatic and brain membranes with IC50 values of 13.7 nM and 2.6 μM, respectively, demonstrating its selectivity for peripheral-type CCK receptors.

AB - Behavioral and receptor binding techniques were employed to evaluate the potency of CR 1409, a new analog of proglumide, as a cholecystokinin antagonist. CR 1409, at doses of 1 mg/kg i.p. in mice, effectively blocked the inhibition of feeding and exploratory behaviors induced by cholecystokinin. In rats, CR 1409 alone, at doses of 1 and 10 mg/kg, did not affect feeding or exploratory behaviors, but at 25 mg/kg alone, CR 1409 reduced food intake and exploratory behaviors, suggesting a mixed agonist-antagonist profile. On these several behavorial parameters, CR 1409 antagonized peripherally administered cholecystokinin with 10-1000 times greater potency than that reported for proglumide (Crawley et al., J. Pharmac. Exp. Ther. 236, 320-330, 1986). In binding to pancreatic cholecystokinin membranes, CR 1409 was more than 100,000-times more potent than that reported for proglumide (Rovati, Scand. J. Gastroenterol. 11, 113-118, 1976). CR 1409 inhabited binding of 125-I-cholecystokinin octapeptide in mouse parcreatic and brain membranes with IC50 values of 13.7 nM and 2.6 μM, respectively, demonstrating its selectivity for peripheral-type CCK receptors.

UR - http://www.scopus.com/inward/record.url?scp=0023184934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023184934&partnerID=8YFLogxK

U2 - 10.1016/0197-0186(87)90083-0

DO - 10.1016/0197-0186(87)90083-0

M3 - Article

AN - SCOPUS:0023184934

VL - 10

SP - 547

EP - 553

JO - Neurochemistry International

JF - Neurochemistry International

SN - 0197-0186

IS - 4

ER -